术后pN0期食管癌辅助性放疗研究进展

摘要

Chest⁃regional recurrence and metastasis are the main modes of treatment failure after surgery for patients with esophageal cancer. As one of the primary approaches for local therapy, radiotherapy has a satisfactory efficacy in the reduction of postoperative chest⁃regional recurrence in patients with esophageal cancer. Right now, the value of postoperative adjuvant therapy for patients with positive lymph nodes has been widely recognized by clinicians. Postoperative adjuvant chemoradiotherapy has become a standard treatment mode. However, there is no consensus on whether adjuvant radiotherapy should be performed in patients with negative lymph nodes. To determine whether patients with stage pN0 esophageal cancer should receive postoperative adjuvant therapy, this paper reviews the current research advances in possible evidence for the necessity of postoperative adjuvant radiotherapy for patients with stage pN0 esophageal cancer, current related reports, and the effects of different surgical methods on treatment outcomes of postoperative adjuvant therapy.%胸腔内—区域复发或和血道转移为食管癌术后患者主要治疗失败模式，作为局部治疗的主要手段之一的放疗在降低食管癌术后患者胸腔内—区域复发的方面具有较好的疗效。目前对于淋巴结阳性患者术后辅助性治疗的价值已得到临床医师的广泛认可，术后辅助性放化疗已然成为了其标准治疗模式。但对于淋巴结阴性的食管癌术后患者是否需要进行辅助性放疗目前并无定论，本文从术后pN0期食管癌患者需进行辅助性放疗的可能依据、目前的相关报道结果和不同手术方式对其的影响等方面综述了目前对于pN0期食管癌术后患者是否需要进行辅助性治疗的研究进展。